Meeting
2020 Genitourinary Cancers Symposium
Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma (aRCC).
Presenter
Robert J. Motzer, MD
Memorial Sloan Kettering Cancer Center
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Rapid Oral Abstract Session
Session Title
Rapid Abstract Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT01668784
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 617)
Abstract #
617
Abstract Disclosures
Similar Videos & Slides
Speaker: William Fraser Symmans, MD
Videos & Slides
2016 Genitourinary Cancers Symposium
CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC).
Speaker: Robert J. Motzer, MD
Speaker: Karen E. Hoffman, MD, MPH
Speaker: Suzanne Louise Topalian, MD